These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1009 related items for PubMed ID: 21296333

  • 1. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
    Page RL, Connolly SJ, Crijns HJ, van Eickels M, Gaudin C, Torp-Pedersen C, Hohnloser SH, ATHENA Investigators.
    Am J Cardiol; 2011 Apr 01; 107(7):1019-22. PubMed ID: 21296333
    [Abstract] [Full Text] [Related]

  • 2. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
    Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH, ATHENA Investigators.
    Circulation; 2009 Sep 29; 120(13):1174-80. PubMed ID: 19752319
    [Abstract] [Full Text] [Related]

  • 3. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
    Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH, EURIDIS and ADONIS Investigators.
    N Engl J Med; 2007 Sep 06; 357(10):987-99. PubMed ID: 17804843
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of dronedarone: a review of randomized trials.
    Christiansen CB, Torp-Pedersen C, Køber L.
    Expert Opin Drug Saf; 2010 Jan 06; 9(1):189-99. PubMed ID: 20001756
    [Abstract] [Full Text] [Related]

  • 5. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter.
    Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W, Torp-Petersen C.
    J Cardiovasc Electrophysiol; 2008 Jan 06; 19(1):69-73. PubMed ID: 18031520
    [Abstract] [Full Text] [Related]

  • 6. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter.
    Khitri AR, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Kowey PR.
    J Cardiovasc Electrophysiol; 2012 May 06; 23(5):462-72. PubMed ID: 22171925
    [Abstract] [Full Text] [Related]

  • 7. A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD.
    J Cardiovasc Pharmacol Ther; 2010 Dec 06; 15(4 Suppl):24S-30S. PubMed ID: 21098416
    [Abstract] [Full Text] [Related]

  • 8. Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
    Duray GZ, Schmitt J, Hohnloser SH.
    J Cardiovasc Pharmacol Ther; 2010 Dec 06; 15(4 Suppl):19S-23S. PubMed ID: 20472812
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study.
    Vamos M, Calkins H, Kowey PR, Torp-Pedersen CT, Corp Dit Genti V, Wieloch M, Koren A, Hohnloser SH.
    Clin Cardiol; 2020 Mar 06; 43(3):291-297. PubMed ID: 31872901
    [Abstract] [Full Text] [Related]

  • 10. Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial.
    Reynolds MR, Lin J, Jhaveri M, Mozaffari E, Plich A.
    Am J Ther; 2014 Mar 06; 21(6):500-8. PubMed ID: 23344106
    [Abstract] [Full Text] [Related]

  • 11. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM, Verma A, Talajic M, Nattel S, Dorian P, CCS Atrial Fibrillation Guidelines Committee.
    Can J Cardiol; 2011 Mar 06; 27(1):47-59. PubMed ID: 21329862
    [Abstract] [Full Text] [Related]

  • 12. Dronedarone: an emerging agent with rhythm- and rate-controlling effects.
    Wegener FT, Ehrlich JR, Hohnloser SH.
    J Cardiovasc Electrophysiol; 2006 Sep 06; 17 Suppl 2():S17-20. PubMed ID: 16939434
    [Abstract] [Full Text] [Related]

  • 13. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
    Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM.
    J Cardiovasc Electrophysiol; 2010 Jun 01; 21(6):597-605. PubMed ID: 20384650
    [Abstract] [Full Text] [Related]

  • 14. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
    Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, Van Kempen L, ERATO Study Investigators.
    Am Heart J; 2008 Sep 01; 156(3):527.e1-9. PubMed ID: 18760136
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
    Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF.
    J Am Coll Cardiol; 2009 Sep 15; 54(12):1089-95. PubMed ID: 19744618
    [Abstract] [Full Text] [Related]

  • 16. Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials.
    Thind M, Crijns HJ, Naccarelli GV, Reiffel JA, Corp Dit Genti V, Wieloch M, Koren A, Kowey PR.
    J Cardiovasc Electrophysiol; 2020 May 15; 31(5):1022-1030. PubMed ID: 32083368
    [Abstract] [Full Text] [Related]

  • 17. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.
    Naccarelli GV, Johnston SS, Lin J, Patel PP, Schulman KL.
    Clin Cardiol; 2010 May 15; 33(5):270-9. PubMed ID: 20513065
    [Abstract] [Full Text] [Related]

  • 18. Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter.
    Kim MH, Lin J, Jhaveri M, Koren A.
    Adv Ther; 2014 Mar 15; 31(3):318-32. PubMed ID: 24595638
    [Abstract] [Full Text] [Related]

  • 19. Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial.
    Blomström-Lundqvist C, Naccarelli GV, McKindley DS, Bigot G, Wieloch M, Hohnloser SH.
    Europace; 2023 Mar 30; 25(3):845-854. PubMed ID: 36758013
    [Abstract] [Full Text] [Related]

  • 20. Dronedarone: current evidence and future questions.
    Schafer JA, Kjesbo NK, Gleason PP.
    Cardiovasc Ther; 2010 Mar 30; 28(1):38-47. PubMed ID: 20074258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.